Synthetic Aluminum-magnesium Silicate Research Articles

Improved Efficacy of Cotrimoxazole with Medicinal Synthetic Aluminum-Magnesium Silicate for Effective Treatment of Trypanosomosis

Improved Efficacy of Cotrimoxazole with Medicinal Synthetic Aluminum-Magnesium Silicate for Effective Treatment of Trypanosomosis

Antivirt<sup>®</sup> {Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>} Cures COVID-19 by Opposite Charges’ Electrostatic Attraction

To cure COVID-19, we propounded mopping viruses/infected cells by opposite-charges electrostatic attraction as mechanism of treatment. RNA viruses (including COVID-19 virus) are positively charged while DNA viruses and abnormal (infected/tumor) cells are negatively charged but normal cells are neutral. Molecules of Aluminum-magnesium silicate (AMS), a WHO- approved medicine, consist of Nanoparticles that have both negatively and positively charged ends. Ultra-small size (0.96 nm thick) of the Nanoparticles, allows them access to cells in all organs. Nigeria does not have natural AMS-deposits but she has Aluminum silicate and Magnesium silicate, abundantly. These solid minerals which are WHO-approved medicines too were used to formulate an AMS-brand, named, Medicinal synthetic AMS (MSAMS, VITUMED®, Antivirt®). Dextrose monohydrate (simple sugar) is incorporated in each MSAMS-formulation to convey the electrically charged Nanoparticles across mucous membranes (active-transportation) into blood for circulation to all organs. The Antivirt® has proved effective against all viral and abnormal-cell diseases so far tested including COVID-19.

Electrostatic Mopping of Viruses with Medicinal Synthetic Aluminum-Magnesium Silicate {Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>}, for Quick Cure of COVID-19: A Better Control Measure

COVID-19 virus has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. Nanoparticles (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication; mopping extra-cellular viruses/abnormal cells; clearing secondary infections; enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for Medicinal synthetic AMS {MSAMS: Al4 (SiO4)3 + 3Mg2SiO4 → 2Al2Mg3 (SiO4)3}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its Nanoparticles into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).

Reducing Side Effects of Chloroquine with <i>Medicinal Synthetic Aluminum-Magnesium Silicate</i>® [Msams: Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> →2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>] before Assessing Its Anti-Covid-19 Efficacy

To reduce Chloroquine’s (CQ) side effects, so that increasing its duration for anti-Covid-19 trials could be safe, the drug was potentiated by stabilizing it with Medicinal synthetic Aluminum-magnesium silicate (MSAMS). CQ-treatment for five Plasmodium berghie-infected mice-groups were: 7 mg/kg (normal dose); 7 mg/kg (CQ-MSAMS); 7 mg/kg (CQ-MSAMS + B-vitamins), 5.25 mg/kg (CQ-MSAMS + B-vitamins) and the control. Means of parasitaemia, 42.00 ± 15.74 of the normal-dose group, 37.22 ± 11.88 of the 7 mg/kg (CQ-MSAMS) group and 33.57 ± 12.62 of the 7 mg/kg (CQ-MSAMS + B-vitamins) group showed no significant (P ≥ 0.05) reduction from 52.50 ± 11.99 of the control, but the 5.25 mg/kg (CQ-MSAMS + B-vitamins) dose, cleared (P ≤ 0.01) the parasiteamia (00.00 ± 00.00), showing that MSAMS-potentiated Chloroquine, has best efficacy at 75% of the recommended dose. Fever and anemia were absent at that 5.25 mg/kg, suggesting that lower doses of CQ have reduced side effects.

Restoring Efficacy to Cotrimoxazole, against Resistant <i>Salmonella pullorum, </i> with <i>Medicinal Synthetic Aluminum-Magnesium Silicate <sup>®</sup></i> [MSAMS: Al<sub>4</sub> (SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub> Mg<sub>3</sub> (SiO<sub>4</sub>)<sub>3</sub>

To restore efficacy (≥95% infection-reduction) to drugs against resistant infections (now, posing a bigger medical challenge, globally, than even HIV/AIDS), Cotrimoxazole was formulated with a synthetic Aluminum-magnesium silicate (Medicinal mineral which molecules are made of Nanoparticles, that is already in use as pharmaceutical-stabilizing agent) and used with antioxidants to treat Cotrimoxazole-resistant Salmonella pulorum infected chicks. Chick-groups A, B and C were fed antioxidants-fortified feed while groups D, E, F, G and H were not. The treatment-groups and their Cotrimoxazole doses/formulations were: A and D (100%/MSAMS-Cotrimoxazole); B and E (75%/MSAMS-Cotrimoxazole); C and F (50%/MSAMS-Cotrimoxazole) and G (100%/Cotrimoxazole). Infection-reductions (96.23% and 94.98%) of the groups of 75%/MSAMS-Cotrimoxazole/antioxidants and 75%/MSAMS-Cotrimoxazole were significantly (P ≤ 0.05) better than 76.99% (100%/Cotrimoxazole); 10.04% (50%/MSAMS-Cotrimoxazole/antioxidants); 1.60% (50%/MSAMS-Cotrimoxazole); −212.60% (100%/MSAMS-Cotrimoxazole/antioxidants) and −230.96% (100%/MSAMS-Cotrimoxazole).

Cure for HIV/AIDS with Medicinal Synthetic Aluminum-Magnesium Silicate {Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>}—A Case Report

HIV/AIDS is an immune deficiency disease, caused by an RNA virus (positively charged pathogen). It is still being regarded as mysteriously incurable but in Nigeria many patients have been cured (they became HIV-antibody and antigen negative) by exploiting electrostatic attraction between pathogens and opposite electrical charges that are on Nanoparticles of Medicinal synthetic Aluminum-magnesium silicate (MSAMS) and by using antioxidants to relieve oxidative stress. To confirm the cure, as permanent, a patient (adult male) whose CD4 count increased (P

HIV/AIDS Recovery Rates in Male and Female Patients, Treated with Medicinal synthetic Aluminum-magnesium silicate

HIV/AIDS Recovery Rates in Male and Female Patients, Treated with Medicinal synthetic Aluminum-magnesium silicate

Clinical Trial of <i>Medicinal Synthetic Aluminum-Magnesium Silicate</i> (Antivirt<sup>®</sup>) on Viral Loads and CD4-Lymphocytes Counts of HIV/AIDS Patients

For clinical trial of Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt®), on viral loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were treated. Their blood samples were tested for viral loads and for CD4-lymphocytes counts, before the treatment and every 4 weeks during the medication. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra protection® (1 tablet/day), for 4 weeks. Then, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When their viral loads become undetectable, they would be treated for additional 4 weeks. Initially, the Antivirt®-regimen appeared to worsen both HIV infection-load and immune deficiency but later relieved them. Patients’ mean-viral load increased (P = 0.020), from 1820.30 ± 868.75 to 2855.90 ± 960.98, after 4 weeks before reducing (P = 0.030) to 1565.20 ± 743.17, after 8 weeks. Similarly, their mean-CD4-lymphocytes count reduced (P = 0.008) from 496.80 ± 194.39 to 263.90 ± 149.26, after 4 weeks before improving (P = 0.001) to 507.90 ± 133.19, after 8 weeks.

Medicinal Synthetic Aluminum-Magnesium Silicate <br/>{Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>} —A Highly Active Anti-Retroviral Medicine

Medicinal synthetic Aluminum-magnesium silicate (MSAMS), which has inhibited Human immune deficiency virus (HIV), in vitro, was used for trial-treatment of HIV/AIDS patients. Their plasma were tested for viral loads (VL): before and repeatedly during the treatment. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra protection?. After 4 weeks, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When VL decreased bellow 50/ml, the treatment continued, 4 weeks before stopping. Mean-VL of four patients increased (P = 0.006) from 498.50 ± 33.37 to 1,072.50 ± 184.55, after 3.75±2.06 weeks and decreased (P = 0.040) to 407.33 ± 297.27 (18.29%) when the treatment-duration increased to 6.67 ± 2.31 weeks. Prolonging the duration to 12.00 ± 2.83 weeks led to 98.68% decrease of mean-VL of four other patients, from 24,250.00 ± 15,939.34 to 321.00 ± 229.38(P = 0.045). Two HIV positive persons treated for 4 weeks after their VL reduced bellow 50/ml have remained healthy, 10 and 16 months respectively, without routine antiretroviral medication.

Enhancing Efficacy of Antimicrobials with the Medicinal Synthetic Aluminum-Magnesium Silicate, for Prevention and Treatment of Resistant Infections

Aim: To achieve, at least, 95% clearance of loads of treated infections so that pathogens do not develop resistance against drugs used for treatment. Materials and Methodology: Lower doses of Aluminum-magnesium silicate (AMS)-stabilized antimicrobials (Piparazine, Ampicillin, Chloroquine and Sulphadimidine), supported with immune stimulants, were used to treat respective sensitive and resistant infections. Results: Recommended doses of Piparazine, Ampicillin and Chloroquine cleared only 82.94%, 80.68% and 20% of Helignosomoides bakeri, Salmonella gallinarum and Plasmodium berghei infections, respectively. Lower doses (75%) of the AMS-stabilized Piparazine and Ampicillin cleared 96.82% and 97.84% of the treated infections. Supporting the lower doses of AMSstabilized Chloroquine and AMS-stabilized Ampicillin with immune stimulants led to 100% clearance of P. berghei infection and 95.80% clearance of Ampicillin-resistant Escherichia coli infection, respectively. Original Research Article Ezeibe and Ogbonna; BJMMR, 9(6): 1-8, 2015; Article no.BJMMR.17768 2 Conclusion: Prolonging bioavailability of drugs with AMS, minimizing side effects of drugs by using their lower doses for treatment, and enhancing immune responses of treated patients, help treatments to prevent and cure resistant infections.

<i>In Vivo</i> Antiretroviral Effects of the Medicinal Synthetic Aluminum-Magnesium Silicate

Viral loads (copies of RNA per ml of plasma) of HIV/AIDS patients, who volunteered for clinical trial of the Medicinal synthetic Aluminum-magnesium silicate, were assessed, before and after they were treated. The treatment lasted 4 weeks, 8 weeks and 12 weeks respectively. A patient who could not access approved laboratory for viral load test on time, continued the treatment for 24 weeks. Following treatment with the medicine, mean viral load of HIV/AIDS patients reduced (P < 0.05) from 18875.00 ± 17059.18 to 327.50 ± 226.84. Rates of the viral load reduction were: 86% after 4 weeks, 96% after 8 weeks and 99.71% after 12 weeks. Clinical signs complained of, by the patients during the treatment, included, fever, dermatitis, boils, joint pain, leg edema and sore throat. These clinical signs ceased when they were treated, so that the antiretroviral treatment was completed. The patient who was on the medication for 24 weeks had no adverse drug reaction.

Assessment of Antiretroviral Effects of a Synthetic Aluminum-magnesium Silicate

Aim: For an affordable therapy for Human immune-deficiency virus (HIV) infections, antiretroviral effects of a synthetic aluminum-magnesium silicate (AMS) were tested. Materials and Methods: Plasma that tested positive to HIV and the AMS were mixed, on equal volume to weight basis, incubated one hour at room temperature and centrifuged for ten minutes at 3,000 revolutions per minute. These procedures were repeated on each supernatant. HIV titres of the two sets of supernatants and the titres in portions of the plasma, not incubated with the AMS were assessed by direct passive hemagglutination test. Results: Mean HIV titres of the plasma increased from 4.00±1.60 to 14.00±2.00 when incubated with the AMS. Repeating the incubation, reduced mean HIV titres in plasma from 14.00±2.00 to 6.50±1.50 (P=0.024). Conclusion: It was concluded that the AMS has antiretroviral effects and could be an Original Research Article British Journal of Medicine & Medical Research, 4(8): 1672-1679, 2014 1673 inexpensive antiretroviral therapy for regular treatment to reduce high rate of HIV infection among low income groups.

Synergy in antibacterial activities of Ampicillin trihydrate, stabilized with a synthetic aluminum-magnesium silicate and immune-stimulants, on resistant &amp;lt;i&amp;gt;Escherichia coli&amp;lt;/i&amp;gt; infection

To treat resistant Escherichia coli infection in chicks, Ampicillin was stabilized with a synthetic aluminum-magnesium silicate (AMS) to prolong its bioavailability. Its dose was also reduced to minimize adverse side effects. Vitamins A, C, E and Selenium levels in the chicks’ feeds were increased to enhance immune response of the chicks. E. coli coloning forming units, per ml of bile of the chicks, treated with Ampicillin and with Ampicillin in AMS, were: 228800.00 ± 90103.50 and 134500.00 ± 44937.97 at 10 mg/kg, 104400.00 ± 36024.44 and 34800.00 ± 8014.97 at 7.5 mg/kg, 198400.00 ± 129301.80 and 156800.00 ± 109392.70 at 5 mg/kg. Mean bacterial loads of the untreated groups, fed normal feed and those fed the fortified feed were 824400.00 ± 322424.80 and 534800.00 ± 277832.80. At 7.5 mg/kg. Ampicillin in the AMS, effectively (P E. coli infection in chicks, fed immune-stimulants, with the infection rate reduced by 95.8%.

Aluminum-Magnesium Silicate enhances release of virions of cultured &amp;lt;i&amp;gt;Fowl Pox Virus&amp;lt;/i&amp;gt; and inhibits the virus

Antiviral effects of a synthetic Aluminum-Magnesium Silicate (AMS) were tested on Fowl Pox Virus (FPV). Five batches of the Nigerian brand of FPV vaccine were used as sources of the virus. The reconstituted vaccines were mixed with The Synthetic AMS on equal volume to weight basis and incubated at room temperature for one hour. They were centrifuged for 10 minutes at 2000 revolutions per minute. The incubation and centrifugation were repeated on a portion of each vaccine supernatant. The two sets of supernatants were tested by the Modified Passive Haemagglutination test, for FPV titres. Portions of the vaccines, not incubated with the AMS, were served as controls. Fowl Pox Virus titres of the vaccines increased from a mean of 2.8 ± 1.10 to 11.2 ± 4.38 when incubated with the AMS once. When incubation with the AMS was repeated, the titres reduced (P